MedTrace Logo

A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial

NCT07104240 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1836

Last updated 2025-08-05

No results posted yet for this study

Summary

This clinical trial compares the effect of a vaccine promotional intervention, TweenVax, to standard of care vaccination promotion practices on rates of human papillomavirus (HPV) vaccination in adolescents. HPV vaccination has been identified as a priority for cancer prevention and control by the Cancer Moonshot Blue Ribbon Panel, which estimated that increasing HPV vaccination rates can prevent 400,000 HPV-related cancers in the next 5-10 years. The goal is for HPV vaccinations to be completed by the age of 13. It has been estimated that only about 16% of adolescents were fully up to date with HPV vaccines by age 13. Strong and consistent provider recommendations have been shown to play an important role in the uptake of vaccines. In addition, education and information received by parents may improve the strength of recommendations by providers. The TweenVax intervention includes practice, provider, parent and patient level education to teach best practices, help with vaccine messaging, and give correct and easy to understand information to parents. Providing practice, provider and parent level access to TweenVax may be more effective than current vaccine promotion practices in improving HPV vaccination rates in adolescents.

Conditions

  • Human Papillomavirus-Related Carcinoma

Interventions

OTHER

Best Practice

Offer standard of care adolescent vaccination promotion practices

OTHER

Educational Intervention

Receive vaccination information

OTHER

Health Promotion and Education

Receive all TweenVax components and trainings for the practice, providers and staff, parents and adolescents

OTHER

Health Promotion and Education

Receive components and trainings for the practice and provider levels

OTHER

Internet-Based Intervention

Receive access to TweenVax application

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Robert Bednarczyk, PhD · Emory University Hospital/Winship Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-02
Primary Completion
2027-03-06
Completion
2028-03-06

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07104240 on ClinicalTrials.gov